<DOC>
	<DOCNO>NCT01336569</DOCNO>
	<brief_summary>The purpose study assess safety intraocular pressure ( IOP ) -lowering efficacy change DuoTrav® prior timolol 0.5 % monotherapy participant open-angle glaucoma ocular hypertension .</brief_summary>
	<brief_title>Safety Efficacy Changing DuoTrav Patients Uncontrolled Timolol</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>Clinical diagnosis ocular hypertension , primary openangle glaucoma pigmentary glaucoma ; Intraocular pressure ( IOP ) 19 35 mmHg time day least one eye ( designate study eye ) ; On stable medication regimen IOP reduction one week prior screen visit ; Best correct visual acuity well 20/200 ( Snellen ) 1.0 ( logMAR ) eye ; Sign inform consent ; Other protocoldefined inclusion criterion may apply . Known medical history allergy , hypersensitivity low tolerance component DuoTrav® ; Any abnormality would preclude reliable performance applanation tonometry either eye ; Infection either eye ; Conventional laser intraocular surgery either eye 3 month prior screen visit ; Risk visual field visual acuity worsening , opinion investigator ; Women childbearing potential ; Pregnant lactate woman ; Any condition , opinion principal investigator , could interfere participation study , could present risk participant . Participation another clinical study within 30 day screen visit ; Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Primary Open-Angle Glaucoma</keyword>
	<keyword>Ocular Hypertension</keyword>
	<keyword>Pigment Dispersion Glaucoma</keyword>
	<keyword>IOP</keyword>
</DOC>